{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:24:14Z","timestamp":1778311454801,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009139","name":"DZIF","doi-asserted-by":"crossref","award":["TTU03.801"],"award-info":[{"award-number":["TTU03.801"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009139","name":"DZIF","doi-asserted-by":"crossref","award":["TTU 03.702"],"award-info":[{"award-number":["TTU 03.702"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009139","name":"DZIF","doi-asserted-by":"crossref","award":["TTU 03.703"],"award-info":[{"award-number":["TTU 03.703"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antibody and cellular memory responses following vaccination are important measures of immunogenicity. These immune markers were quantified in the framework of a vaccine trial investigating the malaria vaccine candidate GMZ2.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Fifty Gabonese adults were vaccinated with two formulations (aluminum Alhydrogel and CAF01) of GMZ2 or a control vaccine (Verorab). Vaccine efficacy was assessed using controlled human malaria infection (CHMI) by direct venous inoculation of 3200 live <jats:italic>Plasmodium falciparum<\/jats:italic> sporozoites (PfSPZ Challenge). GMZ2-stimulated T and specific B-cell responses were estimated by flow cytometry before and after vaccination. Additionally, the antibody response against 212 <jats:italic>P. falciparum<\/jats:italic> antigens was estimated before CHMI by protein microarray.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Frequencies of pro- and anti-inflammatory CD4<jats:sup>+<\/jats:sup> T cells\u00a0stimulated with the vaccine antigen GMZ2 as well as B cell profiles did not change after vaccination. IL-10-producing CD4<jats:sup>+<\/jats:sup> T cells and CD20<jats:sup>+<\/jats:sup> IgG<jats:sup>+<\/jats:sup> B cells were increased post-vaccination regardless of the intervention, thus could not be specifically attributed to any malaria vaccine regimen. In contrast, GMZ2-specific antibody response increased after the vaccination, but was not correlated to protection. Antibody responses to several <jats:italic>P. falciparum<\/jats:italic> blood and liver stage antigens (MSP1, MSP4, MSP8, PfEMP1, STARP) as well as the breadth of the malaria-specific antibody response were significantly higher in protected study participants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In lifelong malaria exposed adults, the main marker of protection against CHMI is a broad antibody pattern recognizing multiple stages of the plasmodial life cycle. Despite vaccination with GMZ2 using a novel formulation, expansion of the GMZ2-stimulated T cells or the GMZ2-specific B\u00a0cell response was limited, and the vaccine response could not be identified as a marker of protection against malaria.<\/jats:p>\n                <jats:p><jats:bold><jats:italic>Trial registration<\/jats:italic><\/jats:bold> PACTR; PACTR201503001038304; Registered 17 February 2015; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=1038\">https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=1038<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-022-04169-8","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T11:26:36Z","timestamp":1655465196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Odilon","family":"Nouatin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4716-0311","authenticated-orcid":false,"given":"Rolf","family":"Fendel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulysse A.","family":"Ngoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freia-Raphaella","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Dejon-Agob\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Ronald","family":"Edoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Fl\u00fcgge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sina","family":"Br\u00fcckner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meral","family":"Esen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Theisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kabirou","family":"Moutairou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian J. F.","family":"Luty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Lell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Kremsner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayola A.","family":"Adegnika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Mordm\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"4169_CR1","unstructured":"WHO. World malaria report 2021. Geneva, World Health Organization, 2021. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2021. Accessed 25 Feb 2022."},{"key":"4169_CR2","doi-asserted-by":"publisher","first-page":"7544","DOI":"10.1016\/j.vaccine.2015.09.099","volume":"33","author":"MT White","year":"2015","unstructured":"White MT, Verity R, Churcher TS, Ghani AC. Vaccine approaches to malaria control and elimination: insights from mathematical models. Vaccine. 2015;33:7544\u201350.","journal-title":"Vaccine"},{"key":"4169_CR3","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.vaccine.2003.09.017","volume":"22","author":"M Theisen","year":"2004","unstructured":"Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H, et al. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine. 2004;22:1188\u201398.","journal-title":"Vaccine"},{"key":"4169_CR4","doi-asserted-by":"publisher","first-page":"e22525","DOI":"10.1371\/journal.pone.0022525","volume":"6","author":"S Belard","year":"2011","unstructured":"Belard S, Issifou S, Hounkpatin AB, Schaumburg F, Ngoa UA, Esen M, et al. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLoS ONE. 2011;6:e22525.","journal-title":"PLoS ONE"},{"key":"4169_CR5","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1016\/j.vaccine.2009.09.011","volume":"27","author":"M Esen","year":"2009","unstructured":"Esen M, Kremsner PG, Schleucher R, Gassler M, Imoukhuede EB, Imbault N, et al. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine. 2009;27:6862\u20138.","journal-title":"Vaccine"},{"key":"4169_CR6","doi-asserted-by":"publisher","first-page":"6698","DOI":"10.1016\/j.vaccine.2010.07.085","volume":"28","author":"B Mordmuller","year":"2010","unstructured":"Mordmuller B, Szywon K, Greutelaers B, Esen M, Mewono L, Treut C, et al. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene. Gabon Vaccine. 2010;28:6698\u2013703.","journal-title":"Gabon Vaccine"},{"key":"4169_CR7","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1016\/j.vaccine.2016.07.041","volume":"34","author":"SB Sirima","year":"2016","unstructured":"Sirima SB, Mordmuller B, Milligan P, Ngoa UA, Kironde F, Atuguba F, et al. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children. Vaccine. 2016;34:4536\u201342.","journal-title":"Vaccine"},{"key":"4169_CR8","doi-asserted-by":"publisher","first-page":"e6950","DOI":"10.1371\/journal.pone.0006950","volume":"4","author":"GJ Gram","year":"2009","unstructured":"Gram GJ, Karlsson I, Agger EM, Andersen P, Fomsgaard A. A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice. PLoS ONE. 2009;4:e6950.","journal-title":"PLoS ONE"},{"key":"4169_CR9","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","volume":"32","author":"JT van Dissel","year":"2014","unstructured":"van Dissel JT, Joosten SA, Hoff ST, Soonawala D, Prins C, Hokey DA, et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine. 2014;32:7098\u2013107.","journal-title":"Vaccine"},{"key":"4169_CR10","doi-asserted-by":"publisher","first-page":"6961","DOI":"10.4049\/jimmunol.171.12.6961","volume":"171","author":"P Sun","year":"2003","unstructured":"Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, et al. Protective immunity induced with malaria vaccine, RTS, S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol. 2003;171:6961\u20137.","journal-title":"J Immunol"},{"key":"4169_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1086\/600120","volume":"200","author":"KE Kester","year":"2009","unstructured":"Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S\/AS01B and RTS, S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200:337\u201346.","journal-title":"J Infect Dis"},{"key":"4169_CR12","doi-asserted-by":"publisher","first-page":"e20775","DOI":"10.1371\/journal.pone.0020775","volume":"6","author":"JM Lumsden","year":"2011","unstructured":"Lumsden JM, Schwenk RJ, Rein LE, Moris P, Janssens M, Ofori-Anyinam O, et al. Protective immunity induced with the RTS, S\/AS vaccine is associated with IL-2 and TNF-alpha producing effector and central memory CD4 T cells. PLoS ONE. 2011;6:e20775.","journal-title":"PLoS ONE"},{"key":"4169_CR13","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/cid\/cix429","volume":"65","author":"G Moncunill","year":"2017","unstructured":"Moncunill G, Mpina M, Nhabomba AJ, Aguilar R, Ayestaran A, Sanz H, et al. Distinct helper T cell type 1 and 2 responses associated with malaria protection and risk in RTS, S\/AS01E vaccinees. Clin Infect Dis. 2017;65:746\u201355.","journal-title":"Clin Infect Dis"},{"key":"4169_CR14","doi-asserted-by":"publisher","first-page":"e18556","DOI":"10.1371\/journal.pone.0018559","volume":"6","author":"ST Agnandji","year":"2011","unstructured":"Agnandji ST, Fendel R, Mestr\u00e9 M, Janssens M, Vekemans J, Held J, et al. Induction of Plasmodium falciparum-Specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS, S\/AS01E and RTS, S\/AS02D. PLoS ONE. 2011;6:e18556.","journal-title":"PLoS ONE"},{"key":"4169_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1592","volume":"13","author":"PA Darrah","year":"2007","unstructured":"Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med. 2007;13:843\u201350.","journal-title":"Nat Med"},{"key":"4169_CR16","doi-asserted-by":"publisher","first-page":"8047","DOI":"10.4049\/jimmunol.0801592","volume":"182","author":"T Lindenstrom","year":"2009","unstructured":"Lindenstrom T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol. 2009;182:8047\u201355.","journal-title":"J Immunol"},{"key":"4169_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nbt.3187","volume":"33","author":"L Lin","year":"2015","unstructured":"Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol. 2015;33:610\u20136.","journal-title":"Nat Biotechnol"},{"key":"4169_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordm\u00fcller","year":"2017","unstructured":"Mordm\u00fcller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542:445\u20139.","journal-title":"Nature"},{"key":"4169_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1126\/science.272.5258.54","volume":"272","author":"R Ahmed","year":"1996","unstructured":"Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science. 1996;272:54\u201360.","journal-title":"Science"},{"key":"4169_CR20","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1128\/IAI.72.9.5412-5418.2004","volume":"72","author":"D Donati","year":"2004","unstructured":"Donati D, Zhang LP, Chene A, Chen Q, Flick K, Nystrom M, et al. Identification of a polyclonal B-cell activator in Plasmodium falciparum. Infect Immun. 2004;72:5412\u20138.","journal-title":"Infect Immun"},{"key":"4169_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3389\/fimmu.2019.00559","volume":"10","author":"A Ly","year":"2019","unstructured":"Ly A, Hansen DS. Development of B cell memory in malaria. Front Immunol. 2019;10:559.","journal-title":"Front Immunol"},{"key":"4169_CR22","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/cid\/ciy1087","volume":"69","author":"JC Dejon-Agobe","year":"2019","unstructured":"Dejon-Agobe JC, Ateba-Ngoa U, Lalremruata A, Homoet A, Engelhorn J, Nouatin OP, et al. Controlled human malaria infection of healthy adults with lifelong malaria exposure to assess safety, immunogenicity, and efficacy of the asexual blood stage malaria vaccine candidate GMZ2. Clin Infect Dis. 2019;69:1377\u201384.","journal-title":"Clin Infect Dis"},{"key":"4169_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12936-015-0628-0","volume":"14","author":"B Mordm\u00fcller","year":"2015","unstructured":"Mordm\u00fcller B, Supan C, Sim KL, G\u00f3mez-P\u00e9rez GP, Ospina Salazar CL, Held J, et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J. 2015;14:117.","journal-title":"Malar J"},{"key":"4169_CR24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12936-015-0817-x","volume":"14","author":"GP Gomez-Perez","year":"2015","unstructured":"Gomez-Perez GP, Legarda A, Munoz J, Sim BK, Ballester MR, Dobano C, et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar J. 2015;14:306.","journal-title":"Malar J"},{"key":"4169_CR25","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4269\/ajtmh.17-0343","volume":"98","author":"B Lell","year":"2018","unstructured":"Lell B, Mordm\u00fcller B, Dejon Agobe JC, Honkpehedji J, Zinsou J, Mengue JB, et al. Impact of sickle cell trait and naturally acquired immunity on uncomplicated malaria after controlled human malaria infection in adults in Gabon. Am J Trop Med Hyg. 2018;98:508\u201315.","journal-title":"Am J Trop Med Hyg"},{"key":"4169_CR26","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1016\/j.vaccine.2020.04.046","volume":"38","author":"O Nouatin","year":"2020","unstructured":"Nouatin O, Ateba Ngoa U, Ibanez J, Dejon-Agobe JC, Mordm\u00fcller B, Edoa JR, et al. Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults. Vaccine. 2020;38:4263\u201372.","journal-title":"Vaccine"},{"key":"4169_CR27","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1038\/s41467-021-22740-w","volume":"12","author":"Z Sulyok","year":"2021","unstructured":"Sulyok Z, Fendel R, Eder B, Lorenz F-R, Kc N, Karnahl M, et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat Commun. 2021;12:2518.","journal-title":"Nat Commun"},{"key":"4169_CR28","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1002\/pmic.200800194","volume":"8","author":"DL Doolan","year":"2008","unstructured":"Doolan DL, Mu Y, Unal B, Sundaresh S, Hirst S, Valdez C, et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics. 2008;8:4680\u201394.","journal-title":"Proteomics"},{"key":"4169_CR29","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/biostatistics\/kxn042","volume":"10","author":"JD Silver","year":"2009","unstructured":"Silver JD, Ritchie ME, Smyth GK. Microarray background correction: maximum likelihood estimation for the normal\u2013exponential convolution. Biostatistics. 2009;10:352\u201363.","journal-title":"Biostatistics"},{"key":"4169_CR30","doi-asserted-by":"publisher","first-page":"e88538","DOI":"10.1371\/journal.pone.0088538","volume":"9","author":"A Pera","year":"2014","unstructured":"Pera A, Campos C, Corona A, Sanchez-Correa B, Tarazona R, Larbi A, et al. CMV latent infection improves CD8+ T response to SEB due to expansion of polyfunctional CD57+ cells in young individuals. PLoS ONE. 2014;9:e88538.","journal-title":"PLoS ONE"},{"key":"4169_CR31","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.crimmu.2021.10.002","volume":"2","author":"W Mandala","year":"2021","unstructured":"Mandala W, Harawa V, Munyenyembe A, Soko M, Longwe H. Optimization of stimulation and staining conditions for intracellular cytokine staining (ICS) for determination of cytokine-producing T cells and monocytes. Curr Res Immunol. 2021;2:184\u201393.","journal-title":"Curr Res Immunol"},{"key":"4169_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","volume":"4","author":"S Awate","year":"2013","unstructured":"Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013;4:114.","journal-title":"Front Immunol"},{"key":"4169_CR33","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1016\/j.vaccine.2011.02.022","volume":"29","author":"S Lousada-Dietrich","year":"2011","unstructured":"Lousada-Dietrich S, Jogdand PS, Jepsen S, Pinto VV, Ditlev SB, Christiansen M, et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2\u2013a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine. 2011;29:3284\u201392.","journal-title":"Vaccine"},{"key":"4169_CR34","doi-asserted-by":"publisher","first-page":"19570","DOI":"10.1038\/srep19570","volume":"6","author":"NP Knudsen","year":"2016","unstructured":"Knudsen NP, Olsen A, Buonsanti C, Follmann F, Zhang Y, Coler RN, et al. Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci Rep. 2016;6:19570.","journal-title":"Sci Rep"},{"key":"4169_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/jbiol34","volume":"5","author":"OR Millington","year":"2006","unstructured":"Millington OR, Di Lorenzo C, Phillips RS, Garside P, Brewer JM. Suppression of adaptive immunity to heterologous antigens during Plasmodium infection through hemozoin-induced failure of dendritic cell function. J Biol. 2006;5:5.","journal-title":"J Biol"},{"key":"4169_CR36","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41590-021-00911-7","volume":"22","author":"SE de Jong","year":"2021","unstructured":"de Jong SE, van Unen V, Manurung MD, Stam KA, Goeman JJ, Jochems SP, et al. Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunity. Nat Immunol. 2021;22:654\u201365.","journal-title":"Nat Immunol"},{"key":"4169_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/mi.2010.8","volume":"3","author":"D Jankovic","year":"2010","unstructured":"Jankovic D, Kugler DG, Sher A. IL-10 production by CD4+ effector T cells: a mechanism for self-regulation. Mucosal Immunol. 2010;3:239\u201346.","journal-title":"Mucosal Immunol"},{"issue":"1197\u2013209","key":"4169_CR38","first-page":"e10","volume":"47","author":"G Triller","year":"2017","unstructured":"Triller G, Scally SW, Costa G, Pissarev M, Kreschel C, Bosch A, et al. Natural parasite exposure induces protective human anti-malarial antibodies. Immunity. 2017;47(1197\u2013209):e10.","journal-title":"Immunity"},{"key":"4169_CR39","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.4049\/jimmunol.0901297","volume":"183","author":"GE Weiss","year":"2009","unstructured":"Weiss GE, Crompton PD, Li S, Walsh LA, Moir S, Traore B, et al. Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol. 2009;183:2176\u201382.","journal-title":"J Immunol"},{"key":"4169_CR40","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357:1903\u201315.","journal-title":"N Engl J Med"},{"key":"4169_CR41","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1182\/blood-2007-11-123844","volume":"111","author":"M Mamani-Matsuda","year":"2008","unstructured":"Mamani-Matsuda M, Cosma A, Weller S, Faili A, Staib C, Gar\u00e7on L, et al. The human spleen is a major reservoir for long-lived vaccinia virus\u2013specific memory B cells. Blood. 2008;111:4653\u20139.","journal-title":"Blood"},{"issue":"32","key":"4169_CR42","doi-asserted-by":"publisher","first-page":"E4438","DOI":"10.1073\/pnas.1501705112","volume":"112","author":"DA Helb","year":"2015","unstructured":"Helb DA, Tetteh KK, Felgner PL, Skinner J, Hubbard A, Arinaitwe E, Mayanja-Kizza H, Ssewanyana I, Kamya MR, Beeson JG, Tappero J, Smith DL, Crompton PD, Rosenthal PJ, Dorsey G, Drakeley CJ, Greenhouse B. Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities. Proc Natl Acad Sci U S A. 2015;112(32):E4438\u201347. https:\/\/doi.org\/10.1073\/pnas.1501705112.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"4169_CR43","doi-asserted-by":"publisher","first-page":"e00027","DOI":"10.1128\/mSphereDirect.00027-19","volume":"4","author":"JM Obiero","year":"2019","unstructured":"Obiero JM, Campo JJ, Scholzen A, Randall A, Bijker EM, Roestenberg M, et al. Antibody biomarkers associated with sterile protection induced by controlled human malaria infection under chloroquine prophylaxis. mSphere. 2019;4:e00027-19.","journal-title":"mSphere"},{"key":"4169_CR44","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/infdis\/jiv224","volume":"212","author":"AE Dent","year":"2015","unstructured":"Dent AE, Nakajima R, Liang L, Baum E, Moormann AM, Sumba PO, et al. Plasmodium falciparum protein microarray antibody profiles correlate with protection from symptomatic malaria in Kenya. J Infect Dis. 2015;212:1429\u201338.","journal-title":"J Infect Dis"},{"key":"4169_CR45","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1038\/srep03549","volume":"3","author":"PL Felgner","year":"2013","unstructured":"Felgner PL, Roestenberg M, Liang L, Hung C, Jain A, Pablo J, et al. Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis. Sci Rep. 2013;3:3549.","journal-title":"Sci Rep"},{"key":"4169_CR46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4269\/ajtmh.15-0037","volume":"93","author":"CL King","year":"2015","unstructured":"King CL, Davies DH, Felgner P, Baum E, Jain A, Randall A, et al. Biosignatures of exposure\/transmission and immunity. Am J Trop Med Hyg. 2015;93:16\u201327.","journal-title":"Am J Trop Med Hyg"},{"key":"4169_CR47","doi-asserted-by":"publisher","first-page":"e00061","DOI":"10.1128\/mSphereDirect.00061-19","volume":"4","author":"T Kobayashi","year":"2019","unstructured":"Kobayashi T, Jain A, Liang L, Obiero JM, Hamapumbu H, Stevenson JC, et al. Distinct antibody signatures associated with different malaria transmission intensities in Zambia and Zimbabwe. mSphere. 2019;4:e00061-19.","journal-title":"mSphere"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04169-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-022-04169-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04169-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:08:25Z","timestamp":1655471305000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-022-04169-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4169"],"URL":"https:\/\/doi.org\/10.1186\/s12936-022-04169-8","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"25 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The original study was approved by the Comit\u00e9 National d\u2019Ethique de la Recherche (CNER) of Gabon, under the reference N\u00b0004\/2015\/SG\/P. The trial was performed according to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines and the Declaration of Helsinki and is registered with the Pan-African Clinical Trials Registry (trial number PACTR201503001038304). Written informed consent was received from all study participants before inclusion into the clinical trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"As CEO of Sanaria Inc., SLH has a potential conflict of interest. All other authors declared that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}